Tolerogenic vaccines for multiple sclerosis

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1032-1038

  Mannie, Mark D ^a   Curtis, Alan D ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Autoimmune disease; Experimental autoimmune encephalomyelitis; Immune; Multiple sclerosis; Myelin; Neuroantigen; T lymphocytes; Therapy; Tolerance; Vaccine

Indexed keywords

ENCEPHALITOGENIC PROTEIN; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[83-99]; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN; TOLEROGENIC VACCINE; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CROSS REACTION; DRUG DESIGN; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; REGULATORY T LYMPHOCYTE;

AUTOIMMUNE DISEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNE; MULTIPLE SCLEROSIS; MYELIN; NEUROANTIGEN; T LYMPHOCYTES; THERAPY; TOLERANCE; VACCINE;

BIOMEDICAL RESEARCH; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE TOLERANCE; MULTIPLE SCLEROSIS; VACCINES;

EID: 84878792694     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23685     Document Type: Note

References (69)

1. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012; 122:1180-8; PMID:22466660; http://dx.doi.org/10.1172/JCI58649.
2. Kuerten S, Lehmann PV. The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis? J Interferon Cytokine Res 2011; 31:907-16; PMID:21936633; http://dx.doi.org/10.1089/jir.2011. 0072.
3. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011; 18:21-9; PMID:20537877; http://dx.doi.org/10.1016/j.pathophys.2010.04.004.
4. Croxford AL, Kurschus FC, Waisman A. Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 2011; 1812:177-83.
5. Batoulis H, Recks MS, Addicks K, Kuerten S. Experimental autoimmune encephalomyelitis - achievements and prospective advances. APMIS 2011; 119:819-30; PMID:22085358; http://dx.doi.org/10.1111/j.1600-0463.2011.02794.x.
6. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Animal models of multiple sclerosis - potentials and limitations. Prog Neurobiol 2010; 92:386-404; PMID:20558237; http://dx.doi.org/10.1016/j.pneurobio.2010.06.005.
7. Wekerle H. Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 2008; 67(Suppl 3):iii56-60; PMID:19022815; http://dx.doi.org/10.1136/ard.2008.098020.
8. Bettelli E. Building different mouse models for human MS. Ann N Y Acad Sci 2007; 1103:11-8; PMID:17376825; http://dx.doi.org/10.1196/annals.1394.021.
9. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129:1953-71; PMID:16632554; http://dx.doi.org/10.1093/brain/awl075.
10. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011; 1812:239-45.
11. Berer K, Wekerle H, Krishnamoorthy G. B cells in spontaneous autoimmune diseases of the central nervous system. Mol Immunol 2011; 48:1332-7; PMID:21146219; http://dx.doi.org/10.1016/j.molimm.2010.10.025.
12. Johnson TA, Jirik FR, Fournier S. Exploring the roles of CD8(+) T lymphocytes in the pathogenesis of autoimmune demyelination. Semin Immunopathol 2010; 32:197-209; PMID:20237782; http://dx.doi.org/10.1007/s00281-010-0199-7.
13. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008; 98:121-49; PMID:18772005; http://dx.doi.org/10.1016/ S0065-2776(08)00404-5.
14. Weiss HA, Millward JM, Owens T. CD8+ T cells in inflammatory demyelinating disease. J Neuroimmunol 2007; 191:79-85; PMID:17920696; http://dx.doi.org/10.1016/j.jneuroim.2007.09.011.
15. McDole J, Johnson AJ, Pirko I. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis. Neurol Res 2006; 28:256-61; PMID:16687050; http://dx.doi.org/10.1179/016164106X98125.
16. Goverman J, Perchellet A, Huseby ES. The role of CD8(+) T cells in multiple sclerosis and its animal models. Curr Drug Targets Inflamm Allergy 2005; 4:239-45; PMID:15853746; http://dx.doi.org/10.2174/1568010053586264.
17. Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, et al. Evolution of MS lesions to black holes under DNA vaccine treatment. J Neurol 2012; 259:1375-82; PMID:22222856; http://dx.doi.org/10.1007/s00415-011-6361-x.
18. Mannie MD, Blanchfield JL, Islam SM, Abbott DJ. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol 2012; 3:255; PMID:22934095; http://dx.doi.org/10.3389/ fimmu.2012.00255.
19. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012; 30:1217-24; PMID:23159881; http://dx.doi.org/10.1038/nbt.2434.
20. de Andrade Pereira B, Fraefel C, Hilbe M, Ackermann M, Dresch C. Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis. Gene Ther 2012; PMID:22951454; http://dx.doi.org/10.1038/gt.2012.73.
21. Kaushansky N, Kerlero de Rosbo N, Zilkha-Falb R, Yosef-Hemo R, Cohen L, Ben-Nun A. 'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides. PLoS One 2011; 6:e27860; PMID:22140475; http://dx.doi.org/10.1371/ journal.pone.0027860.
22. Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, Feeney EM, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol 2011; 187:2405-17; PMID:21821796; http://dx.doi.org/10.4049/jimmunol. 1004175.
23. Zhang AH, Li X, Onabajo OO, Su Y, Skupsky J, Thomas JW, et al. B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells. J Autoimmun 2010; 35:107-13; PMID:20579844; http://dx.doi.org/10.1016/j. jaut.2010.05.002.
24. Stern JN, Keskin DB, Kato Z, Waldner H, Schallenberg S, Anderson A, et al. Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc Natl Acad Sci U S A 2010; 107:17280-5; PMID:20855626; http://dx.doi.org/10.1073/pnas.1010263107.
25. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 2010; 22:609-15; PMID:20850958; http://dx.doi.org/10.1016/j.coi.2010.08.006.
26. Peron JP, Yang K, Chen ML, Brandao WN, Basso AS, Commodaro AG, et al. Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice. J Neuroimmunol 2010; 227:10-7; PMID:20580440; http://dx.doi.org/10.1016/j.jneuroim.2010.06.002.
27. Song F, Guan Z, Gienapp IE, Shawler T, Benson J, Whitacre CC. The thymus plays a role in oral tolerance in experimental autoimmune encephalomyelitis. J Immunol 2006; 177:1500-9; PMID:16849456.
28. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004; 20:695-705; PMID:15189735; http://dx.doi.org/10.1016/j.immuni.2004.05.002.
29. Bynoe MS, Evans JT, Viret C, Janeway CA Jr. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 2003; 19:317-28; PMID:14499108; http://dx.doi.org/10.1016/S1074-7613(03)00239-5.
30. Chastain EM, Miller SD. Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunol Rev 2012; 245:227-38; PMID:22168423; http://dx.doi.org/10.1111/j.1600-065X.2011.01076.x.
31. Kakalacheva K, Munz C, Lunemann JD. Viral triggers of multiple sclerosis. Biochim Biophys Acta 2011; 1812:132-40.
32. Lucas RM, Hughes AM, Lay ML, Ponsonby AL, Dwyer DE, Taylor BV, et al. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 2011; 82:1142-8; PMID:21836034; http://dx.doi.org/10.1136/jnnp-2011-300174.
33. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009; 22:201-6; PMID:19359987; http://dx.doi.org/10. 1097/WCO.0b013e32832b4c8d.
34. Kidd BA, Ho PP, Sharpe O, Zhao X, Tomooka BH, Kanter JL, et al. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res Ther 2008; 10:R119; PMID:18826638; http://dx.doi.org/10.1186/ar2523.
35. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11:335-9; PMID:15735651; http://dx.doi.org/10.1038/nm1202.
36. Ellmerich S, Mycko M, Takacs K, Waldner H, Wahid FN, Boyton RJ, et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 2005; 174:1938-46; PMID:15699121.
37. Schubert DA, Gordo S, Sabatino JJ Jr., Vardhana S, Gagnon E, Sethi DK, et al. Self-reactive human CD4 T cell clones form unusual immunological synapses. J Exp Med 2012; 209:335-52; PMID:22312112; http://dx.doi.org/10.1084/jem. 20111485.
38. Rosenthal KM, Edwards LJ, Sabatino JJ Jr., Hood JD, Wasserman HA, Zhu C, et al. Low 2-dimensional CD4 T cell receptor affinity for myelin sets in motion delayed response kinetics. PLoS One 2012; 7:e32562; PMID:22412888; http://dx.doi.org/10.1371/journal.pone.0032562.
39. Sabatino JJ Jr., Huang J, Zhu C, Evavold BD. High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J Exp Med 2011; 208:81-90; PMID:21220453; http://dx.doi.org/10. 1084/jem.20101574.
40. Goverman JM. Immune tolerance in multiple sclerosis. Immunol Rev 2011; 241:228-40; PMID:21488900; http://dx.doi.org/10.1111/j.1600-065X.2011.01016.x.
41. Sabatino JJ Jr., Rosenthal KM, Evavold BD. Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. J Neuroimmune Pharmacol 2010; 5:176-88; PMID:19904613; http://dx.doi.org/10.1007/ s11481-009-9181-3.
42. Abbott DJ, Blanchfield JL, Martinson DA, Russell SC, Taslim N, Curtis AD, et al. Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE). BMC Immunol 2011; 12:72; PMID:22208499; http://dx.doi.org/10.1186/1471-2172-12-72.
43. Blanchfield JL, Mannie MD. A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC. J Leukoc Biol 2010; 87:509-21; PMID:20007248; http://dx.doi.org/10.1189/jlb.0709520.
44. Wortham C, Grinberg L, Kaslow DC, Briles DE, McDaniel LS, Lees A, et al. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect Immun 1998; 66:1513-20; PMID:9529075.
45. Jones T, Stern A, Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994; 13(Suppl 2):S47-53; PMID:7875153; http://dx.doi.org/10.1007/BF01973602.
46. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6:1167-75; PMID:11017150; http://dx.doi.org/10.1038/80516.
47. Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunol 2012; 3:233; PMID:22876246; http://dx.doi.org/10.3389/ fimmu.2012.00233.
48. Fukaya T, Takagi H, Taya H, Sato K. DCs in immune tolerance in steady-state conditions. Methods Mol Biol 2011; 677:113-26; PMID:20941606; http://dx.doi.org/10.1007/978-1-60761-869-0-8.
49. Nasreen M, Waldie TM, Dixon CM, Steptoe RJ. Steady-state antigen-expressing dendritic cells terminate CD4+ memory T-cell responses. Eur J Immunol 2010; 40:2016-25; PMID:20405475; http://dx.doi.org/10.1002/eji. 200940085.
50. Doan T, McNally A, Thomas R, Steptoe RJ. Steady-state dendritic cells continuously inactivate T cells that escape thymic negative selection. Immunol Cell Biol 2009; 87:615-22; PMID:19581919; http://dx.doi.org/10.1038/icb.2009.46.
51. Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, Klatzmann D, Liblau R, et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 2003; 198:737-46; PMID:12939344; http://dx.doi.org/10.1084/jem.20030686.
52. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi.org/10.1084/jem.20021598.
53. Pletinckx K, Döhler A, Pavlovic V, Lutz MB. Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells. Front Immunol 2011; 2:39; PMID:22566829; http://dx.doi.org/10.3389/fimmu.2011.00039.
54. Kornete M, Piccirillo CA. Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I diabetes. Autoimmun Rev 2011; 11:104-11; PMID:21875694; http://dx.doi.org/10.1016/j.autrev.2011.08.007.
55. Elong Ngono A, Pettré S, Salou M, Bahbouhi B, Soulillou JP, Brouard S, et al. Frequency of circulating autoreactive T cells committed to myelin determinants in relapsing-remitting multiple sclerosis patients. Clin Immunol 2012; 144:117-26; PMID:22717772; http://dx.doi.org/10.1016/j.clim.2012. 05.009.
56. Grau-López L, Raïch D, Ramo-Tello C, Naranjo-Gómez M, Dàvalos A, Pujol-Borrell R, et al. Myelin peptides in multiple sclerosis. Autoimmun Rev 2009; 8:650-3; PMID:19393199; http://dx.doi.org/10.1016/j.autrev. 2009.02.013.
57. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004; 172:3893-904; PMID:15004197.
58. Burns J, Bartholomew B, Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol 1999; 45:33-9; PMID:9894874; http://dx.doi.org/ 10.1002/1531-8249(199901)45:1〈33::AID-ART7〉3.0.CO;2-G.
59. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998; 101:725-30; PMID:9466965; http://dx.doi.org/10.1172/ JCI1528.
60. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998; 160:1532-8; PMID:9570577.
61. Uccelli A, Giunti D, Salvetti M, Ristori G, Fenoglio D, Abbruzzese, et al. A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clin Exp Immunol 1998; 111:186-92; PMID:9472680; http://dx.doi.org/10.1046/j.1365-2249.1998.00457.x.
62. Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS inf lammation: MOG and more. Ther Adv Neurol Disord 2012; 5:147-59; PMID:22590479; http://dx.doi.org/10.1177/1756285611433772.
63. Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012; 69:752-6; PMID:22371853.
64. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367:115-23; PMID:22784115; http://dx.doi.org/10.1056/NEJMoa1110740.
65. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77:580-8; PMID:21795651; http://dx.doi.org/ 10.1212/WNL.0b013e318228c0b1.
66. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183:4067-76; PMID:19687098; http://dx.doi.org/10.4049/jimmunol.0801888.
67. Quandt JA, Huh J, Baig M, Yao K, Ito N, Bryant M, et al. Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol 2012; 189:2897-908; PMID:22888134; http://dx.doi.org/10.4049/jimmunol.1103087.
68. Luckey D, Bastakoty D, Mangalam AK. Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice. J Autoimmun 2011; 37:122-8; PMID:21632210; http://dx.doi.org/ 10.1016/j.jaut.2011.05.001.
69. Madsen LS, Andersson EC, Jansson L, krogsgaard M, Andersen CB, Engberg J, et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999; 23:343-7; PMID:10610182; http://dx.doi.org/10. 1038/15525.2